Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCTI.L Regulatory News (CTI)

  • There is currently no data for CTI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Statement relating to UK FCA enforcement action

31 May 2019 10:51

RNS Number : 7638A
Cathay International Holdings Ld
31 May 2019
 

Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR).

Cathay International Holdings Limited

("Cathay" or the "Company")

Statement relating to UK FCA enforcement action

Hong Kong, 31 May 2019: In 2017 the Financial Conduct Authority ("FCA") commenced an Enforcement investigation into Cathay International Holdings Limited ("Cathay") and certain of its directors under section 97 Financial Services and Markets Act 2000 to establish whether Cathay may have committed certain breaches of the Listing Principles and Disclosure and Transparency Rules and whether certain directors may have been knowingly concerned in those breaches.

On 24 May 2019, following conclusion of that investigation, the FCA issued Cathay with a Decision Notice imposing a financial penalty of £411,000 for breaches of Listing Principle 1, Disclosure and Transparency Rule ("DTR") 2 and Premium Listing Principle 6 between 21 August 2015 and 29 December 2015 and Listing Principle 2 between 29 February 2016 and 16 August 2016. The penalty comprises £261,000 for the breaches of Listing Principle 1, DTR 2.2.1R and Premium Listing Principle 6 and £150,000 for the breach of Listing Principle 2.

The FCA also issued a Decision Notice to Cathay's CEO, Mr Jinyi Lee, for knowing concern in those breaches and to Cathay's Finance Director, Mr Eric Siu, for knowing concern in the breach of Listing Principle 2.

Cathay, Mr Lee and Mr Siu do not agree with the FCA's findings and penalty and are considering whether to refer the FCA's decision to the Upper Tribunal.

The FCA's findings in greater detail

The FCA has found that between 21 August 2015 and 29 December 2015, Cathay breached Listing Principle 1 by failing to take reasonable steps to establish and maintain adequate procedures, systems and controls to enable it to comply with its obligations as a listed company:

· in how Cathay prepared forecasts of its expected year-end financial performance; and

· in how Cathay monitored its expected year-end financial performance against market expectations.

The FCA has also found that between 6 December 2015 and 29 December 2015 Cathay breached DTR 2.2.1R and Premium Listing Principle 6 by failing to disclose to the market as soon as possible inside information relating to its expected financial performance for the year ended 31 December 2015.

Finally, the FCA has also found that between 29 February 2016 and 16 August 2016, although there was no intention to mislead, Cathay breached Listing Principle 2 by providing different information to that which the FCA had requested in correspondence relating to the events in 2015, without any explanation. .

Cathay's response

As to Listing Principle 1, Cathay does not accept that its systems and controls were inadequate.

Cathay's position was that it had a well-established system for preparing year-end forecasts twice annually, based on projections submitted by each of its subsidiaries, and for receiving and considering ongoing financial data from each of its subsidiaries monthly. As it was advised to do, Cathay compared its forecasts, when they were prepared, against market estimates. Special circumstances in August 2015 meant that Cathay was unable to prepare a quantified forecast for its main subsidiary Lansen, but Cathay does not accept that this indicates a weakness systems and controls. Cathay rejected that any breach of Listing Principle 1 was committed recklessly. 

As to DTR 2 and Premium Listing Principle 6, Cathay denied that it was in possession of any inside information. Cathay also denied that any breach of the DTRs and Premium Listing Principle 6 which did occur was committed recklessly as it had a genuine belief that additional sales could bring its performance in-line with market expectations.

As to Listing Principle 2, Cathay emphasises (as the FCA has accepted) that Cathay did not intend to mislead the FCA.

Cathay, Mr Lee and Mr Siu, are considering whether to refer the FCA's decision to the Upper Tribunal.

The FCA has not yet published the Decision Notices issued to Cathay, Mr Lee and Mr Siu. The FCA's approach is to decide on a case-by-case basis whether to publish a Decision Notice, but the FCA expects normally to do so if the subject of enforcement action refers the matter to the Upper Tribunal. The FCA may also publish a Decision Notice before a person has decided whether to refer the matter to the Upper Tribunal if the FCA considers there is a compelling reason to do so. The deadline for making a reference to the Upper Tribunal is 28 days from the date the Decision Notices were given.

-Ends-

 

For further enquiries, please contact:

 

Cathay International Holdings Limited

Eric Siu (Finance Director)

Patrick Sung (Director and Controller)

 

 

Tel: +852 2828 9289

 

Consilium Strategic Communications

Mary-Jane Elliott / Matthew Neal / Lindsey Neville

 

 

Tel: +44 (0) 203 709 5702

 

 

About Cathay

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on investment opportunities in the growing domestic demand for high quality healthcare products in the PRC and build portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a track record of identifying investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

 

The Group employs approximately 1,600 people across the PRC, including over 20 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRLIFSAETILVIA
Date   Source Headline
1st Apr 20118:59 amRNSGrant of Share Options
24th Mar 20119:02 amRNSAnnual Report and Accounts
18th Mar 20119:09 amRNSGrant of share options
16th Mar 20117:00 amRNSAnnual Results for the Year Ended 31 December 2010
10th Mar 20119:55 amRNSNotice of Results
9th Mar 20117:00 amRNSAppointment of Adviser
29th Nov 20107:30 amRNSZhejiang Starry Pharmaceutical Co., Ltd.
19th Nov 20107:27 amRNSInterim Management Statement
16th Nov 20107:00 amRNSZhejiang Starry Pharmaceutical Co., Ltd.
26th Aug 20105:04 pmRNSINTERIM RESULTS 2010
4th Jun 20107:00 amRNSResults of AGM and change of Director's role
1st Jun 20107:06 amRNSLansen Pharmaceutical Holdings - Update
19th May 20103:32 pmRNSInterim Management Statement
12th May 201010:37 amRNSAnnual Information Update
6th May 20107:32 amRNSLansen Pharmaceutical Holdings Company Limited
27th Apr 20104:25 pmRNSLansen Pharmaceutical Holdings Company Limited
27th Apr 20104:22 pmRNSPRELIMINARY RESULTS
19th Apr 20101:41 pmRNSResult of Special General Meeting
16th Apr 201012:38 pmRNSSpecial General Meeting on 19 April 2010
6th Apr 20105:18 pmRNSPublication of Circular
1st Apr 20101:09 pmRNSLansen Pharmaceutical Holdings Company
23rd Mar 20109:00 amRNSAdditional Listing
26th Feb 20109:07 amRNSAdditional Listing
12th Feb 20106:06 pmRNSUpdate on further investment in Xian Haotian Group
26th Jan 20105:18 pmRNSAnnual Information Update
21st Jan 20105:56 pmRNSAppointment of Directors and Issue of Equity
7th Dec 20099:11 amRNSTotal Voting Rights and Share Capital
4th Dec 200911:16 amRNSResult of SGM
4th Dec 20097:06 amRNSResult of Placing Open Offer
19th Nov 200911:03 amRNSInterim Management Statement
18th Nov 20095:24 pmRNSPublication of Prospectus
18th Nov 20097:00 amRNSPlacing and Open Offer
26th Aug 20092:00 pmRNSInterim Results 2009
22nd Jul 20094:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20094:35 pmRNSPrice Monitoring Extension
26th May 200911:08 amRNSHolding(s) in Company
1st May 20099:30 amRNSDirectorate Change
1st May 20099:28 amRNSResult of AGM
1st May 20097:00 amRNSDIRECTORATE CHANGE
14th Apr 20091:45 pmRNSInterim Management Statement
6th Apr 20095:30 pmRNSPRELIMINARY RESULTS
23rd Jan 200912:27 pmRNSAnnual Information Update
19th Nov 200811:04 amRNSInterim Management Statement
12th Sep 20082:09 pmRNSFurther Update on Xian Haotian
29th Aug 20084:00 pmRNSInterim Results
30th May 20083:18 pmRNSResult of AGM and SGM
19th May 20087:30 amRNSInterim Management Statement
29th Apr 20082:47 pmRNSFinal Results
29th Apr 20088:39 amRNSXian Haotian Circular
28th Apr 20082:09 pmRNSCirc re Xian Haotian

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.